. Based on the above findings, a diagnosis of myelodysplastic syndrome (MDS), 5q deletion (5q−) was considered. Conventional karyotyping and GTG-banding was done. Twenty metaphases were screened and fifteen karyotyped [ Figure 3 ]. The result was interpreted according to International System for Human Cytogenetic Nomenclature (1995). There was interstitial deletion of long arm of chromosome 5 and reported as 46, XX, del (5) (q13q33), thus confirming our initial diagnosis. Fluorescent in situ hybridization indicated 5q− in 40% of analyzed cells.
MDS encompasses a group of acquired disorders that are usually characterized by peripheral blood cytopenias, dysplasia, and clonal proliferation of hematopoietic cells resulting in ineffective erythropoiesis. Prognosis is highly variable with nearly 30% of the cases progressing to acute leukemia. [1] 5q− syndrome is recognized as a distinct entity by the WHO. [2] Documented studies from different parts of the world show that this subtype is the most common, occurring in 10%-20% of the patients with MDS. Unpublished data from our center show an incidence of 6%. The disease presents commonly in middle age, more often in women and unlike other subtypes of MDS they carry favorable prognosis with rare transformation to acute myeloid leukemia. [3] It has been postulated that the disease arises from bone marrow stem cell. [4] These patients typically present with macrocytic anemia, normal to elevated platelet counts, dysplastic megakaryocytes, <1% myeloblasts, and isolated karyotype aberration involving interstitial deletion of long arm of chromosome 5. The size of deletion and breakpoints may be varied commonly being a 1.5 MB segment extending from bands 5q31 to 5q33. [5] Studies have shown that a subset of patients with 5q− have additional chromosomal aberration, conversely, 5q− may be seen in other myeloid disorders. These tend to carry worse prognosis depending on the nature of aberration and do not fall in the category of 5q− MDS. While approaching a case of refractory anemia in an elderly, a differential diagnosis of 5q− MDS must be kept in mind as targeted therapy for the disease is available and it carries a good prognosis. 
Pediatric Plasmablastic Lymphoma: Diagnostic and Therapeutic Dilemma
Editor, Plasmablastic lymphoma (PBL) is an aggressive subtype of diffuse large B-cell lymphoma, characterized by proliferation of large neoplastic cells with immunoblastic/plasmacytic morphology. [1] Most patients present in advanced stage with frequent bone marrow (BM) and extranodal involvement, commonly, oral cavity/jaw. [2] The disease is more common in adults [1, 3] with only about 21 children reported till date. [4] BM involvement has been reported in about one-third of cases [4] but is difficult to recognize in children because the tumor is morphologically and immunologically indistinguishable from multiple myeloma and other lymphomas with plasmacytoid differentiation, [1] conditions equally unexpected in the diagnostic setting in this age group. Here, we present the clinical and hematological features of two children with PBL.
The first patient, an 8-year-old child, presented with mass in the left maxillary area with proptosis, high-grade fever, weight loss, and rapid diminution of vision [ Figure 1 ]. Positron emission tomography (PET) showed diffuse uptake in all bones of the body and computed tomography scan showed a maxillary mass extending into the floor of orbit and roof of the mouth. Orbital biopsy was reported elsewhere as high-grade lymphoma with plasmacytic differentiation, based on the presence of sheets of large cells with eccentric nuclei, prominent nucleoli, frequent mitoses, and a few binucleate and multinucleated cells. Peripheral smear showed neutrophilia without rouleaux formation or plasma cells. BM smears showed sheets of plasma cells with eccentric nuclei and hof. Flow cytometry showed these cells to be immunophenotypically similar to plasma cells/myeloma cells -CD38+, CD138+, CD56+, CD19−, CD20−, and CD45 dim . The patient was seropositive for HIV. A final diagnosis of PBL was made. The patient was put on NHL-BFM 90 standard protocol of treatment. [5] The patient was improving until 10 weeks into treatment and died as a result of progression.
The second patient, a 12-year-old boy, presented with a 4-month history of pain in shoulder and hip and fever for 1 month. PET scan showed multiple lytic lesions all over the body. Blood chemistry revealed hypercalcemia. Blood counts and hormonal assays for parathormone and thyroid function tests were normal. A very faint band was seen on high-resolution electrophoresis of serum in the fast gamma region, but immunofixation electrophoresis was normal. BM smears showed infiltration by approximately 20% abnormal lymphoid cells which were plasmacytoid. Biopsy from soft tissue mass in the upper arm showed sheets of plasmacytic cells that were LCA+, CD138+, CD56+, CD10+, CD1a−, CD3−, MPO−, TdT−, and CD20−. Viral screen was negative. A final diagnosis for PBL was made. The patient was put on NHL-BFM 90 protocol and has been off therapy for 4 months.
PBL occurs more commonly in immunocompromised patients in the setting of transplant or HIV positivity. [3] PBL may occasionally be the initial presentation of HIV as was seen in our first patient. Diagnosis in both our patients required exclusion of plasmablastic variant of multiple myeloma. [1] Features that favor PBL over multiple myeloma include association with HIV 
